Moderna (MRNA) Operating Income (2017 - 2026)
Moderna (MRNA) reported Operating Income of -$1.4 billion for Q1 2026, down 32.19% year-over-year from -$2.0 billion in Q1 2025, and down 61.96% quarter-over-quarter from -$857.0 million in Q4 2025.
Moderna (MRNA) Operating Income (2017 - 2026) Analysis & Trends
Moderna (MRNA) has 10 years of Operating Income data on file, last reported at -$1.4 billion in Q1 2026.
- Operating Income for Q1 2026 came in at -$1.4 billion, down 32.19% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.4 billion (up 8.5% YoY), and the FY2025 annual result was -$3.1 billion, up 22.08% from the prior year.
- Operating Income slipped to -$1.4 billion in Q1 2026 per MRNA's latest filing, from -$857.0 million in the prior quarter.
- Over five years, Operating Income peaked at $4.2 billion in Q1 2022 and troughed at -$2.0 billion in Q3 2023.
- A 5-year average of -$189.8 million and a median of -$857.0 million in 2025 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2024: Operating Income jumped 233.89% in 2022, then slumped 20866.67% in 2024.
- A 5-year view of Operating Income shows it stood at $1.6 billion in 2022, then plunged by 99.62% to $6.0 million in 2023, then tumbled by 20866.67% to -$1.2 billion in 2024, then jumped by 31.22% to -$857.0 million in 2025, then slumped by 61.96% to -$1.4 billion in 2026.
- Business Quant data shows MRNA's Operating Income at -$1.4 billion in Q1 2026, -$857.0 million in Q4 2025, and -$260.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Moderna | 25.27 Bn | 20.06 Bn | -566.00 Mn | -1.39 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.39 Bn |
| Dec 31, 2025 | -857.00 Mn |
| Sep 30, 2025 | -260.00 Mn |
| Jun 30, 2025 | -907.00 Mn |
| Mar 31, 2025 | -1.05 Bn |
| Dec 31, 2024 | -1.25 Bn |
| Sep 30, 2024 | -70.00 Mn |
| Jun 30, 2024 | -1.36 Bn |
| Mar 31, 2024 | -1.27 Bn |
| Dec 31, 2023 | 6.00 Mn |
| Sep 30, 2023 | -2.01 Bn |
| Jun 30, 2023 | -1.87 Bn |
| Mar 31, 2023 | -366.00 Mn |
| Dec 31, 2022 | 1.58 Bn |
| Sep 30, 2022 | 1.17 Bn |
| Jun 30, 2022 | 2.45 Bn |
| Mar 31, 2022 | 4.23 Bn |
| Dec 31, 2021 | 5.41 Bn |
| Sep 30, 2021 | 3.56 Bn |
| Jun 30, 2021 | 3.06 Bn |